Cell Communication and Signaling (Jan 2025)

O-GlcNAcylated FTO promotes m6A modification of SOX4 to enhance MDS/AML cell proliferation

  • Junjie Gou,
  • Jingjing Bi,
  • Kexin Wang,
  • Lei Lei,
  • Yanli Feng,
  • Zengqi Tan,
  • Jiaojiao Gao,
  • Yanan Song,
  • Enci Kang,
  • Feng Guan,
  • Xiang Li

DOI
https://doi.org/10.1186/s12964-025-02058-6
Journal volume & issue
Vol. 23, no. 1
pp. 1 – 13

Abstract

Read online

Abstract Fat mass and obesity-associated protein (FTO) was the first m6A demethylase identified, which is responsible for eliminating m6A modifications in target RNAs. While it is well-established that numerous cytosolic and nuclear proteins undergo O-GlcNAcylation, the possibility of FTO being O-GlcNAcylated and its functional implications remain unclear. This study found that a negative correlation between FTO expression and O-GlcNAcylation in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The decreased O-GlcNAcylation on FTO can result in diminished m6A modification of SRY-related high mobility group box 4 (SOX4). This led to the promotion of cell apoptosis and inhibition of cell proliferation in MDS/AML. The O-GlcNAcylation of FTO stabilized SOX4 transcripts in an m6A-dependent manner, resulting in increased AKT and MAPK phosphorylation and decreased cell apoptosis. Inhibiting FTO O-GlcNAcylation significantly slowed AML progression in vitro, a finding supported by clinical data in MDS/AML patients. In conclusion, our study highlights the crucial role of FTO O-GlcNAcylation in RNA m6A methylation and the progression of MDS/AML, thereby providing a potential therapeutic avenue for these formidable diseases.

Keywords